TG Therapeutics TGTX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's interest expense?
- TG Therapeutics (TGTX) reported interest expense of $7.67M in Q1 2026.
- How has TG Therapeutics's interest expense changed year-over-year?
- TG Therapeutics's interest expense increased by 13.5% year-over-year, from $6.76M to $7.67M.
- What is the long-term trend for TG Therapeutics's interest expense?
- Over 4 years (2021 to 2025), TG Therapeutics's interest expense has grown at a 47.6% compound annual growth rate (CAGR), from $5.64M to $26.73M.
- What does interest expense mean?
- The total cost of interest paid on the company's debt.
- How do you interpret interest expense?
- An increase suggests higher debt levels or rising interest rates, while a decrease indicates debt reduction or refinancing at better terms.
- How does interest expense compare across companies?
- Varies significantly based on capital structure and industry-standard debt-to-equity ratios.